• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Newsletter Sign Up
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • Supervision of Medical Device Business Operation in China – 2022 Regulatory Updates

Supervision of Medical Device Business Operation in China – 2022 Regulatory Updates

supervision of medical device business
Monday, 25 April 2022 / Published in Medical Device, News, NMPA Registration in China

Supervision of Medical Device Business Operation in China – 2022 Regulatory Updates

Supervision of medical device business operation in China will be strengthened when the new regulatory measures come into effect on May 1, 2022.

On March 22, 2022, the National Medical Products Administration (NMPA) published (No.54-2022) the amended version of the Administrative Measures for the Supervision of Medical Device Business Operation to replace the previous CFDA Order No.8 announced on July 30, 2014.

Supervision of Medical Device Business Operation – Highlights

The key points about which medical device manufacturers should be aware have been summarised by our regulatory experts below.

  • Business license and some other supporting materials will no longer be required in the application of obtaining business operation approval. The dossier submission and on-site inspection can be carried out once if the same applicant applies for class III medical device business operation approval and the filing of class II medical device business operation at the same time. If the class III medical device business operation approval has already been obtained, the submission of the corresponding information for the filing of class II medical device can be exempted.
  • The internal review for business operation approvals will be reduced from 30 working days to 20 working days.
  • The NMPA announced a list of 13 class II medical devices that will be exempted from business operation filing as the effectiveness and safety of the product won’t be affected by the distribution process. Medical device registrants or filers that are selling the products in their own residential address or manufacturing sites, as well as non-profit organizations handling the storage, distribution, and supply of contraceptive medical devices will all be exempted from business operation filing.
  • Public statement declaring the loss of the business operation approval certificate will no longer be required to apply for a new certificate.

On March 22, 2022, the NMPA published (No.53-2022) the amended version of the Administrative Measures for the Supervision of Medical Device Manufacturing to replace the previous CFDA Order No.7 announced on July 30, 2014. Read our separate blog post for more information.

By Julie Zhang and Jacky Li. If you would like to learn more about supervision of medical device business operations in China or our registration and CRO services for medical devices, IVDs, pharmaceuticals, cosmetics or other products, please contact Cisema.

Tagged under: medical device, medical device business operation

What you can read next

NMPA Issues Charging Standards for Drug and Medical Device Registration
China – Updates for voluntary product safety certification (instead CCC)
Public Consultation on Chemical Detection and Efficacy Evaluation Methods in Cosmetics

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • Submission of safety information for cosmetics ingredients

    Submission of safety information for cosmetics raw materials – Draft guidelines issued

    Submission of safety information for cosmetics ...
  • avoid animal testing in Chinaweb-2023

    How to avoid animal testing in China for cosmetics | Cisema Webinar

    China’s beauty and cosmetic market has be...
  • guidelines for medical devices registration

    Guidelines for medical devices registration in China – New development plans in 2023

    Guidelines for medical devices registration in ...
  • China DMF of API

    China DMF of API, Excipient & Packaging Materials: Market & Regulatory | Cisema Webinar

    “China DMF of API, Excipient & Packag...
  • pre-phase III drug clinical trial meeting guidelines

    Pre-phase III drug clinical trial meeting guidelines released

    Pre-phase III drug clinical trial meeting guide...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP